Brain Delivery Strategic opportunity to partner on cross BBB delivery capabilities leveraging Ossianix’s shark-derived VNAR platform to transport biologics into the brain for neurodegeneration, ALS, neurooncology and pain programs.

Strategic Partnerships Target collaborations with pharma focused on CNS and metabolic diseases, building on past partnerships with Lundbeck and Novo Nordisk to accelerate BBB shuttle technologies and expand therapeutic modalities.

Biologic Advantage Position Ossianix as a specialist enablement partner for hard-to-deliver targets, offering rapid-high affinity VNAR-based constructs to extend reach beyond conventional antibodies for CNS and brain-adjacent therapies.

Early-stage Value Align with their preclinical stage and small team size to pursue co-development or sponsored research deals that leverage early biology, neurodegeneration and pain programs with faster decision timelines.

Funding & Growth Capitalize on their funding history and revenue signals to propose milestone-driven collaborations, potential licensing, or strategic investment discussions to scale preclinical programs.